Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Change from Baseline at Month 3 in 24-Hour Mean SBP Assessed by Ambulatory Blood Pressure Monitoring (ABPM)

Time frame: Baseline and Month 3

Change from Baseline at Month 6 in Mean Seated Office SBP

Time frame: Baseline and Month 6

Change from Baseline at Month 6 in 24-Hour Mean SBP Assessed by ABPM

Time frame: Baseline and Month 6

Proportion of Patients with Mean Seated Office SBP <140 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6

Time frame: Month 6

Proportion of Patients with 24-hour Mean SBP assessed by ABPM <130 mmHg and/or Reduction ≥10 mmHg without Intensification of Antihypertensive Regimen at Month 6

Time frame: Month 6

Change from Baseline at Month 3 and Month 6 in Daytime and Nighttime Mean SBP and Diastolic Blood Pressure (DBP) assessed by ABPM

Time frame: Baseline and Months 3 and 6

Change from Baseline at Month 3 and Month 6 in Mean Seated Office DBP

Time frame: Baseline and Months 3 and 6

Change from Baseline at Month 3 and Month 6 in 24-hour Mean DBP Assessed by ABPM

Time frame: Baseline and Months 3 and 6

Change from Baseline Over Time in Serum Angiotensinogen (AGT)